On Wednesday, shares of commercial-stage biotech company Travere Therapeutics (TVTX) rose significantly by nearly 14%, largely driven by the latest reports from two analysts. Jefferies analyst Maury Raycroft included Travere in a list of companies that could become acquisition targets by 2026, specifically noting that its drug Filspari is a highly valuable asset with the potential to become a blockbuster.
Filspari has been submitted to the U.S. Food and Drug Administration for the treatment of focal segmental glomerulosclerosis, with a final decision date set for January 13, 2026. The drug previously received full approval in early 2024 for the treatment of immunoglobulin A nephropathy.
At the same time, Cantor Fitzgerald’s report pointed out that the U.S. Food and Drug Administration may show some flexibility in reviewing Filspari’s new indications, providing a positive signal for the drug’s prospects. Citi analyst Yigal Nochomovitz also maintained a buy rating and a $48 target price for Travere Therapeutics. While the acquisition potential is noteworthy, analytical views emphasize that the optimism about the company is based more on the likelihood of Filspari reaching or approaching blockbuster status, rather than solely on merger and acquisition expectations. These positive assessments collectively drove investors to buy the stock ahead of the holidays, contributing to the strong surge in its price.
